NCI Cancer Bulletin: A Trusted Source for Cancer Research News
NCI Cancer Bulletin: A Trusted Source for Cancer Research News
May 1, 2007 • Volume 4 / Number 16 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

FDA Update

Genentech and FDA Issue Warning on Bevacizumab

On April 21, the FDA and Genentech notified health care professionals of new safety information about the formation of tracheoesophageal (TE) fistulas in a clinical study of patients with small-cell lung cancer (SCLC). The trial combined chemotherapy and radiation plus bevacizumab (Avastin). One fatal and one serious adverse event of TE fistula have been confirmed among the first 29 patients enrolled in the study. A third, fatal event of suspected TE fistula was also reported but has not been confirmed. Six other cases of TE fistula have also been reported in other lung and esophageal cancer studies using bevacizumab.

Bevacizumab is not approved for the treatment of SCLC. Genentech intends to revise the bevacizumab package insert to include more detailed information regarding the incidence of all cases of fistula in patients treated with bevacizumab.

Complete information is available at: